Pfizer Inc. $PFE Shares Sold by CSM Advisors LLC

CSM Advisors LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,026 shares of the biopharmaceutical company’s stock after selling 185,354 shares during the period. CSM Advisors LLC’s holdings in Pfizer were worth $17,071,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer in the second quarter worth $2,270,157,000. Fisher Asset Management LLC lifted its position in shares of Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after acquiring an additional 3,296,415 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.0%

Shares of NYSE:PFE opened at $26.60 on Friday. The stock’s 50-day moving average price is $26.50 and its two-hundred day moving average price is $25.52. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The firm has a market cap of $151.23 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on PFE shares. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. HSBC reissued a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.05.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.